Zhaoyan New Pharmaceutical (06127) released interim results with net loss of 170 million yuan year-on-year profit to loss

According to Zhitong Finance App, Zhaoyan New Pharmaceutical (06127) announced its 2024 semi-annual results. The group achieved operating income of 849 million yuan (RMB, same below) during the period, a year-on-year decrease of 16.08%; net loss attributable to shareholders of listed companies was 170 million yuan; net profit attributable to shareholders of listed companies was 906.272 million yuan during the same period last year; a basic loss of 0.23 yuan per share.

According to the announcement, from 2019 to the first half of 2024, a total of about 1,600 biopharmaceuticals, 1,180 chemical drugs, and more than 50 non-clinical research projects were added; the company is in a leading position in the country in terms of the number of non-clinical evaluation projects for new drugs and the number of non-clinical evaluation projects for new biological drugs.